NEW YORK, (February 28, 2019) – Finn Partners strengthens and expands Health Practice senior leadership within its New York office with the promotion of Michael Heinley to senior partner from partner; appointment of Ann Hemingway as partner; and the newly formed medical and scientific advisory services led by former Johnson & Johnson medical affairs leader, Joseph Hulihan, MD.
“As FINN continues to experience industry-leading growth, we recognized the need to expand our senior leadership team, and our capabilities to address the significant opportunity to meet the needs of client and the patient communities,” said Kristie Kuhl, JD, managing partner, New York and Chicago Health Groups and US Pharma Team. “We’re thrilled to recognize the contributions of leaders such as Michael Heinley, and to strengthen FINN client services with seasoned industry pros Ann Hemingway and Dr. Hulihan.”
Recognized as the US Healthcare Agency of the Year and a top five global healthcare agency by The Holmes Report, and most recently by the Observer as its #1 Power PR Firm in Health, the Finn Partners Health Practice is among the agency’s largest and fastest growing units.
Senior Staff Promotions & Appointments
Michael Heinley has served as partner and deputy of the New York Health Group since 2016. His promotion to senior partner recognizes the significant contribution to FINN leadership, growth and staff development across the Health Practice. Heinley manages client teams spanning biopharma, medical devices, diagnostics, and advocacy organizations, and he also champions the Practice healthtech accounts group and global collaboration.
Heinley is a frequent editorial contributor and speaker on issues affecting the health industry, such as pricing, reputation, issues management, marketing and the transforming digital health environment. Heinley is a health industry veteran with more than 25 years of experience, including leadership roles at Johnson & Johnson, Merck and WebMD. He serves on the Board of Directors of Donate Life New York State. Heinley holds a B.A. in Journalism from Temple University.
Ann Hemingway joins as a partner in FINN New York Health Group. Hemingway plays an important role within several biopharma accounts. Hemingway is an accomplished PR professional with more than 20 years of experience leading global and US health accounts. Her career has focused on pharmaceutical product communications including the development, launch and management of programs and cross-functional teams on a large scale including multiple geographies and disciplines.
Prior to joining FINN, Hemingway was senior vice president at Edelman and oversaw several portfolios of business and integrated communication campaigns. She also has worked at Ogilvy and HAVAS. Hemingway graduated from Miami University, Oxford Ohio, with a B.S. in Mass Communication.
Heinley and Hemingway report to Kristie Kuhl, JD, managing partner, New York and Chicago Health Groups and US Pharma Team.
FINN Medical & Scientific Advisory Services
“Navigating the health ecosystem requires deep insights and expertise that informs communication strategies to align patient, provider, payer, policymaker, product and service sector interests,” said Gil Bashe, managing partner, Global Health Practice. “Dr. Joe Hulihan joining our agency as advisor reinforces our dedication to client service and our dedication to ensure patients can make informed decisions based on accurate information.”
Joe Hulihan, MD, MS-HP, former head of Johnson & Johnson’s Janssen Neuroscience Medical Affairs, serves as medical and scientific advisor to the FINN Health Practice. In this advisory role, Dr. Hulihan provides medical and scientific input and day-to-day guidance to ensure content is medically accurate and compliant with regulatory requirements and valuable to patient communities. Dr. Hulihan also provides staff training and practical medical insight surrounding disease education, product and scientific communication strategies and related activities for data communications, medical expert engagement, medical affairs studies, clinical research programs, and product/data analyses.
Prior to establishing his consulting practice in 2015, Dr. Hulihan worked at Johnson & Johnson in neuroscience drug development and medical affairs for 15 years. He was involved in drug development and post-approval medical support for numerous therapeutic areas. He holds a Master of Science degree in Health Policy from Thomas Jefferson University, bachelor’s degree from Dickinson College in Carlisle, PA, and attended medical school at Drexel University School of Medicine, completing a neurology residency at Hahnemann Hospital in Philadelphia and a fellowship at Mayo Clinic. Prior to joining Johnson & Johnson, Dr. Hulihan was Associate Professor of Neurology at Temple University School of Medicine, and Director of the EEG Laboratory and Clinical Neurophysiology fellowship program at Temple University Hospital.
About Finn Partners, Inc.
Founded in 2011 on the core principles of innovation and collaborative partnership, Finn Partners has quadrupled in size in seven years, becoming one of the fastest growing independent public relations agencies in the world. The full-service marketing and communications company’s record setting pace is a result of organic growth and integrating new companies and new people into the FINN world through a common philosophy. With almost 700 professionals, FINN provides its clients with global access and capabilities in the U.S., Europe and Asia, in addition to PROI Worldwide. Headquartered in New York, FINN’s other offices are located in: Boston, Chicago, Detroit, Hong Kong, Fort Lauderdale, Frankfurt, Jerusalem, London, Los Angeles, Munich, Nashville, Paris, Portland, San Francisco, Shanghai, Singapore and Washington D.C. Find us at finnpartners.com and follow us on Twitter and Instagram at @finnpartners.